美股市場個股詳情
RARE Ultragenyx Pharmaceutical
- 44.240
- +0.390+0.89%
收盤價 04/26 16:00 (美東)
- 43.310
- -0.930-2.10%
盤後 16:05 (美東)
36.43億總市值-5362市盈率TTM
44.575最高價43.710最低價45.04萬股成交量44.160今開43.850昨收1992.32萬成交額0.62%換手率虧損市盈率(靜)8233.57萬總股本54.98052周最高13.23市淨率31.93億流通值31.52052周最低--股息TTM7217.17萬流通股179.647歷史最高--股息率TTM1.97%振幅31.520歷史最低44.232平均價1股每手
關於Ultragenyx Pharmaceutical公司
Ultragenyx Pharmaceutical Inc 是一家總部位於美國的生物製藥公司。 它識別、收購、開發和商業化用於治療嚴重罕見和超罕見疾病的新產品，重點是嚴重的、使人衰弱的遺傳疾病。 該公司的藥品組合包括 Crysvita、Dojolvi 和 Mepsevii。 Crysvita 適用於治療成人和 1 歲及以上兒童患者的 X 連鎖低磷血癥 (XLH)。 Mepsevii 適用於兒童和成人患者，用於治療粘多糖貯積症 VII。
公司介紹
公司代碼RARE
公司名稱Ultragenyx Pharmaceutical
上市日期2014/01/31
發行價格21.00
成立日期2010
CEODr. Emil D. Kakkis, M.D.,PhD
所屬市場納斯達克
員工數量1276
證券類型海外普通股
年結日12-31
公司地址60 Leveroni Court
城市Novato
省份加利福尼亞州
國家美國
郵編94949
電話1-415-483-8800
董事高管
- 姓名
- 職務
- 年薪
- Dr. Emil D. Kakkis, M.D.,PhD
- Director, President, Chief Executive Officer
- 1214.03萬
- Erik Harris
- Chief Commercial Officer and Executive Vice President
- 374.86萬
- Dennis Karl Huang
- Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations
- --
- Howard Horn
- Chief Financial Officer and Executive Vice President, Corporate Strategy
- --
- Karah Parschauer
- Chief Legal Officer and Executive Vice President
- --
- Thomas R. Kassberg
- Chief Business Officer and Executive Vice President
- 233.17萬
- Dr. Eric Crombez, M.D.
- Executive Vice President and Chief Medical Officer
- --
- John Richard Pinion, II
- Chief Quality Officer and Executive Vice President, Translational Sciences
- 370.65萬
- Theodore A. Huizenga
- Senior Vice President, Corporate Controller and Chief Accounting Officer
- --
- Daniel G. Welch
- Chairman of the Board
- 49.94萬
- Matthew K. Fust
- Independent Director
- 47.82萬
- Dr. Deborah L. Dunsire,M.D.
- Independent Director
- 46.22萬
- Dr. Corsee Dating Sanders, PhD
- Independent Director
- 46.58萬
- Michael A. Narachi
- Independent Director
- 48.13萬
- Dr. Amrit Ray
- Independent Director
- 124.16萬
- Dr. Shehnaaz Suliman, M.D.
- Independent Director
- 46.64萬
- Dr. Camille L. Bedrosian,M.D.
- Strategic Development Advisor
- 375.53萬
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅